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Visceral leishmaniasis (VL) or Kala-azar is a protozoal disease, which was previously regarded as one of the most neglected 
tropical diseases. Management of this disease is quite difﬁ  cult, because it is said to affect the poorest of the poor. Previously 
Sodium Stibogluconate (SSG) was regarded as the gold standard treatment for VL. But due to the increasing unresponsive-
ness, to this drug various other drugs were tried and are still being tried. Pentamidine is very toxic and has been discarded 
of late. Amphotericin B and its lipid formulations are very effective but require hospital admission and monitoring. Oral 
drugs like Miltefosine have already been launched. An amino glycoside Paromomycin and another oral drug Sitamaquine 
are in the pipe line. Interferon gamma has been used with discouraging results.
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Visceral leishmaniasis (VL) or Kala-azar is vector borne disease, caused by a protozoan parasite, Leishmania donovani and 
transmitted by the bite of female sand-ﬂ  y, Phlebotomus argentipes in India. It can also be caused by L. infantum, L. chagasi, 
and viscerotropic strains of L. amazonensis, L. maxicana and L. tropica. Moreover, there are other vectors than P. argentipes. 
It is prevalent in more than 80 countries in Asia, Africa, Southern Europe and South America. It is estimated that every year 
about 5 00,000 new cases occur worldwide. Of these, 90% cases occur in ﬁ  ve countries namely India, Nepal, Bangladesh, 
Brazil and Sudan. India alone contributes to 50% of the global burden of VL yearly and 90% of this occur in North Bihar 
only.
1 Epidemics have occurred in India more so in the state of Bihar. The disease is clinically characterized by prolonged 
fever, hepatosplenomegaly and pancytopenia. These days, there are challenges in the chemotherapy of kala-azar like 
(a) widespread resistance to antimonials, (b) safe and cost effective medications with less toxicity, (c) HIV leishmania 
co-infection and its rising incidence and (d) the non availability of an effective vaccine.
2
Parenteral Drugs
Sodium stibogluconate
It was the initial drug to be used for the management of VL, in the dose of 10 mg/Kg for 6 to 10 days. 
But due to increasing unresponsiveness, its dose was modiﬁ  ed and the standard WHO recommendation, 
at present, is 20 mg/Kg for 30 days deep intra muscular. In one study, the unresponsiveness to sodium 
stibogluconate (SSG) in Bihar State and particularly in highly endemic districts was of the order of 
60%. SSG still remains the drug of choice for VL outside Bihar.
3
The exact mechanism of action is still not very clear. It is said to inﬂ  uence the bioenergetics of 
leishmania parasite by inhibiting parasite glycolysis, fatty acid ß oxidation and inhibition of ADP phos-
phorylation. It may also promote efﬂ  ux of thiols mainly glutathione and trypanothione.
4 The main toxic 
effects are cardiotoxicity, especially myocarditis and arthritis besides acute tubular necrosis in a few 
cases. The cure rate at present has come down to as low as 45% in the endemic districts of Bihar.
Pentamidine Isethionate
It is an aromatic diamidine and was previously, used as a second line drug. Its anti-leishmanial activity, 
is due possibly to polyamine biosynthesis and its effect on mitochondrial membrane potential. The dose 2
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is 4 mg/Kg intravenously slowly on alternate days 
for 15 injections and has a present cure rate of about 
70%. However, because of multiple toxic effects 
like anaphylactic shock, nephrotoxicity and diabe-
tes mellitus (in about 10% of the patients) its use 
has been restricted and has been discarded 
of late.
Amphotericin B
This is an anti-fungal macrolide antibiotic, which 
was shown to have anti-leishmanial activity in the 
late 1960s. Its main mechanism of action, is due 
to its selective afﬁ  nity for position-24 substituted 
sterols mainly ergosterol. It also causes formation 
of aqueous pores resulting in cell lysis. At a dose 
of 1 mg/Kg body weight for 15 injections in 5% 
dextrose intravenously, either on alternate days or 
daily the cure rate has been shown to be as high as 
98%.
5 Primary unresponsiveness and relapses are 
very uncommon. The main side effects include 
chills and rigor, thrombophlebitis, occasionally 
myocarditis, hypokalaemia, renal dysfunction and 
death. The drug needs prolonged hospitalization 
and close monitoring for toxicity including elec-
trocardiogram (ECG) and serum electrolytes.
Lipid formulations of Amphotericin B have 
advantages like (a) minimum toxicity, (b) short dura-
tion of therapy and (c) target speciﬁ  city (i.e. it is 
delivered directly to the parasitized reticulo- 
endothelial system cells). The main draw back is, 
however, its high cost which limits its use in devel-
oping countries like India. Three lipid formula-
tions are available (a) liposomal Amphotericin B 
(Ambisome), (b) Amphotericin B lipid complex 
(Abelcet) and (c) Amphotericin B colloidal dispersion 
(Amphocil). In Indian patients, Ambisome in a dose 
of 3 to 5 mg/kg for ﬁ  ve days or 15 mg/kg as a single 
dose cured all patients (100%) even in refractory 
cases.
6 The cost of a single dose of 5 mg/kg of 
Ambisome for a 30 kg patient is about Rs. 27,000 
(US$574.47) as compared to Rs. 2700 (US$57.45) 
for a typical course of Amphotericin B deoxycholate. 
All in all, Amphotericin B and its lipid formulations 
are probably the best in the list of drugs used for 
treating VL at present.
Paromomycin
It is an injectable aminoglycoside anti-leishmanial 
drug.
7 In Phase III multicentric trial (of which 
Rajendra Memorial Research Institute of Medical 
Sciences, Patna was also a part), a ﬁ  nal cure rate of 
94% was reported. The drug was used in the dose of 
15 mg/kg/day for 21 days intramuscularly. The main 
side effects, as with other aminoglycosides, nephro-
toxicity and ototoxicity fortunately were of a very 
low degree. This drug has the potential to replace 
SSG as the ﬁ  rst line of drug for VL. Problem of 
treatment failure and relapses have to be assessed 
when used as monotherapy. Phase IV trials of the 
drug are due to start soon at various clinical centres 
of Bihar.
Oral Compounds
Miltefosine
This is an alkyl phospholipid compound which 
was previously used as a topical application for 
the skin metastasis of breast cancer. The main 
anti-leishmanial activity is due to modulation of 
cell surface receptors, inositol metabolism, phos-
pholipase activation and protein kinase C besides 
mitogenic pathways resulting in apoptosis.
8 This 
drug has a long half life of about 150 to 200 hours, 
thereby raising concerns for emergence of resis-
tance.
9 The dose is 2.5 mg/kg/day in divided 
doses orally for 28 days. Phase III and Phase IV 
trials at this center and various other centers have 
demonstrated a ﬁ  nal cure rate of about 94%. It 
is one of the few drugs which even though being 
an anti-neoplastic agent, stimulate the bone mar-
row thereby leading to correction of pancytope-
nia. The main side effects of the drug include 
gastrointestinal disturbances like nausea, diar-
rhoea and vomiting in about 20 to 30% of the 
cases. The symptoms are transient or reversible 
despite (during) ongoing treatment and not a 
cause of major concern. In the phase III trial, 
alanine transaminase (ALT) and aspartate trans-
aminase (AST) levels were raised in the ﬁ  rst 
week (AST) or occasionally towards the end 
(both AST and ALT). These relations did not 
require treatment modiﬁ  cation. Renal toxicity 
was observed in a few cases. The drug is not to 
be used in pregnancy due to its possible terato-
genic effect. However, in phase IV trial, three 
female patients became pregnant during the fol-
low up period. All the three had full term normal 
pregnancy and the fetuses were devoid of any 
teratogenic effects. This drug can prove to be a 
ﬁ  rst line drug and the expert committee has rec-
ommended for its use in the elimination of VL 
programme in India.3
Pharmacotherapeutic options for visceral ieishmaniasis—current scenario
Clinical Medicine: Pathology 2009:2
Azoles
These are sterol biosynthesis inhibitors and were 
shown to be effective against wide range of pro-
mastigotes and amastigotes. But their anti-
leishmanial activity was not enough to induce 
clinical cure by themselves. Ketoconazole and 
ﬂ  uconazole are two drugs that were used for VL 
in this group.
Sitamaquine
This is an orally active 8-aminoquinoline analogue 
and its effectiveness in VL was validated in animal 
models. It is still in phase I and II trial stages. In 
one of the multicentric phase II trials (of which 
this center is also a part) it is being used in the dose 
of 2 mg/kg/day orally for 21 days. In another pre-
vious phase II trial in Kenya as well as India, the 
cure rate was about 50%. The main toxic effects 
were renal, like glomerulonephritis and acute 
tubular necrosis.
10
New investigational products 
in pre-clinical phases
Licochalcone A, derived from Chinese liquorice 
plant Glycyrrhiza, has shown reasonable oral efﬁ  -
cacy in experimental models of VL as well as 
Cutaneous leishmaniasis (CL). One derivative gave 
97% suppression of L. donovani liver amastigotes 
in a hamster model. Another compound from a 
Vietnamese plant Maesa balanasae showed sig-
niﬁ  cant activity in VL models. Isopropylquino-
lines, isolated from Galipea longiﬂ  ora inboligia, 
has also shown activity in VL models. Biphospho-
nates, used for osteoporosis, have been found to 
be effective against both VL and CL. Two of these 
drugs, risedronate and pamidronate, have also been 
found to be effective.
11
Immunomodulators
Due to the intracellular nature of leishmania para-
site, VL patients usually require an interferon-
gamma (IFN-γ) dominant T-helper cell type 1 
(Th1) pro-inﬂ  ammatory response for clearing of 
the parasite. As such, it was felt that the IFN-γ 
dominant inflammatory mechanism, would be 
required to support the efﬁ  cacy of conventional 
anti-leishmanial chemotherapy.
12 However, clini-
cal trials with gamma interferon in combination 
with SSG, were very disappointing in that they 
gave a cure rate of about 50%. Besides, this is very 
costly and requires cold chain for storage.
HIV–leishmania co-infection
This combination is assuming dangerous propor-
tions worldwide, more so in Southwest Europe and 
India. The management of such cases is very dif-
ﬁ  cult because of (a) frequent relapses, (b) dosage 
and duration of the drugs to be administered 
have not been validated and (c) drug-drug 
interactions.
Pentavalent antimonials need to be given for 
a prolonged period which can lead to severe 
cardiac toxicity. The cure rate is low, about 50 to 
60%. Amphotericin B in the dose of 1 mg/kg/day 
for 28 days had a cure rate of about 62%. 
Amphotericin B lipid complex in the dose of 
4 mg/kg/day on days 1–5, 10, 17, 24, 31 and 38 
was well tolerated. Miltefosine was used in one 
patient with good results.
13 This inspired a 
whole series of compassionate use in patients 
over the following years.
14,15 These days 
various drug combinations are being tried. 
These include (a) SSG 20 mg/kg/day for 
28 days + Paromomycin 50 mg/kg/day for 
28 days,
16 (b) SSG 20 mg/ kg/day for 28 days + 
Amphotericin B 1 mg/kg/day for 28 days, 
(c) SSG 20 mg/kg/day for 28 days + Allopurinol 
20 mg/kg/day for 28 days,
17 (d) SSG 20 mg/kg/day 
for 28 days + gamma interferon 100 μg/m
2/day 
for 28 days,
18 (e) Miltefosine 2.5 mg/kg/day for 
28 days + SSG 20 mg/kg/day for 28 days or 
Amphotericin B 1 mg/kg/day for 28 days and 
(f) Miltefosine 100 mg/day for 28 days + 
Amphotericin B 1 mg/kg/day for 28 days. These 
drugs are being tried at various centres all over 
the world. All these patients, are also to be admin-
istered highly active anti-retroviral therapy 
(HAART) depending on CD4 count level (if less 
than 200/μl), besides treatment of other oppor-
tunistic infections. However, drug interactions 
with HAART, mainly non-nucleoside reverse 
transcriptase inhibitors like nevirapine, protease 
inhibitors like indinavir, sequanavir etc. and anti-
tuberculous drugs like rifampicin need to be 
taken into consideration, as most of these patients 
suffer from tuberculosis as well.
19
In conclusion, it is to be stated that in the last 
three decades unresponsiveness to pentavalent 
antimonials in certain parts of Bihar has arisen 
to 60%. As a result, Amphotericin B is considered 4
Pandey et al
Clinical Medicine: Pathology 2009:2
to be the best drug at present. However, it is 
relatively much costlier as compared to SSG. 
Newer drugs like Miltefosine are very promising, 
but costly. Paromomycin seems to be another effec-
tive therapeutic option with low cost. Future strat-
egies should be made to save new potent drugs 
from acquiring resistance and better management 
of co-infection cases. This can open up a gate for 
combination therapy. A few new indigenous plant 
extracts as well as synthetic compounds, having 
anti-leishmanial activity, need to be explored for 
its safety and efﬁ  cacy in VL treatment through 
clinical trials. Further more, studies should be 
under taken to test the efﬁ  cacy of second generation 
anti-leishmanial vaccine as prophylaxis.
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